# Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

> **NCT02475317** · PHASE1 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Placebo
- **DRUG:** Maralixibat
- **DRUG:** Volixibat

## Key facts

- **NCT ID:** NCT02475317
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2015-12-01
- **Final completion:** 2015-12-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475317, "Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02475317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*